Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $36.7100 (-0.62%) ($36.7100 - $36.7100) on Mon. Jul. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.85% (three month average) | RSI | 42 | Latest Price | $36.7100(-0.62%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.425% in a week (0% probabilities). VIXM(-46%) VXX(-38%) UUP(-19%) UNG(-4%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.425% (StdDev 2.85%) | Hourly BBV | -0.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $38.45 | 5 Day Moving Average | $37.33(-1.66%) | 10 Day Moving Average | $38.08(-3.6%) | 20 Day Moving Average | $38.45(-4.53%) | To recent high | -17.6% | To recent low | 13.2% | Market Cap | $4.649b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |